Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents-Reference-Cited by-同舟云学术

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents

Published:2001-09 Issue:17 Volume:11 Page:2241-2244
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Seefeld Mark A,Miller William H,Newlander Kenneth A,Burgess Walter J,Payne David J,Rittenhouse Stephen F,Moore Terrance D,DeWolf Walter E,Keller Paul M,Qiu Xiayang,Janson Cheryl A,Vaidya Kalindi,Fosberry Andrew P,Smyth Martin G,Jaworski Deborah D,Slater-Radosti Courtney,Huffman William F

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference14 articles.

1. The Crisis in Antibiotic Resistance

2. New Directions in Antibacterial Research

3. Fatty acid metabolism in bacteria

4. The Enoyl-[Acyl-Carrier-Protein] Reductase (FabI) of Escherichia coli, which Catalyzes a Key Regulatory Step in Fatty Acid Biosynthesis, Accepts NADH and NADPH as Cofactors and is Inhibited by Palmitoyl-CoA

5. Enoyl-Acyl Carrier Protein Reductase (fabI) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cupferron impairs the growth and virulence of Escherichia coli clinical isolates;Journal of Applied Microbiology;2023-10

2. Recent Advancements in Indole Derivatives and their Antimicrobial Perspective;Letters in Organic Chemistry;2023-08

3. GCN-Based Structure-Activity Relationship and DFT Studies of Staphylococcus aureus FabI Inhibitors;International Journal of Quantitative Structure-Property Relationships;2022-11-04

4. An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections;ACS Central Science;2022-08-10

5. Classification of Staphylococcus Aureus FabI Inhibitors by Machine Learning Techniques;Research Anthology on Machine Learning Techniques, Methods, and Applications;2022-05-13